Trial reportJournal of diabetes science and technology2018
Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes.
Trial report in Journal of diabetes science and technology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A 6-week Randomised, Double-blind, Parallel-group Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes
Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes
Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy: To Assess How the 670G System Adapts to the Introduction of Fiasp® Insulin
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Advances in Insulin Infusion Set in the New Era of Automated Insulin Delivery: A Systematic Review.Journal of diabetes science and technology · 2023Pooled it
- Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-Blind, Crossover Study in Men With Type 1 Diabetes.Diabetes care · 2021Trial
- Fast-Acting Insulin Aspart Use with the MiniMedDiabetes technology & therapeutics · 2021Trial
- Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial.Diabetes technology & therapeutics · 2020Trial
- A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).Diabetes, obesity & metabolism · 2019Trial
- Patient-specific deep offline artificial pancreas for blood glucose regulation in type 1 diabetes.Smart health (Amsterdam, Netherlands) · 2026Article
- The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus.Journal of diabetes science and technology · 2025Article
- Can Faster Aspart Be Used to Optimize Glycemic Control With Insulin Pump Therapy? From Expectations to Lessons Learned After a Year of Use in the United States.Clinical diabetes : a publication of the American Diabetes Association · 2022Article
- Dual-hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions.Artificial organs · 2021Review
- Improvements in Glycemic Control Achieved by Altering the tDiabetes therapy : research, treatment and education of diabetes and related disorders · 2021Article
- Ultrafast acting insulin analog - a new way to prevent postprandial hyperglycemia and improve quality of life in type 1 diabetes patients - case reports.Pediatric endocrinology, diabetes, and metabolism · 2021Article
- The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications.Diabetes, obesity & metabolism · 2020Review
- Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences.Clinical pharmacokinetics · 2020Review
- Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019Review
- Use of fast-acting insulin aspart in insulin pump therapy in clinical practice.Diabetes, obesity & metabolism · 2019Review
- Improving pregnancy outcomes in women with diabetes mellitus: modern management.Nature reviews. Endocrinology · 2019Review
- Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus.Clinical pharmacokinetics · 2019Review
- First User Experiences With a Novel Touchscreen-Based Insulin Pump System in Daily Life of Patients With Type 1 Diabetes Experienced in Insulin Pump Therapy.Journal of diabetes science and technology · 2019Article
- Pump Users Clamor for Faster Insulin: Is Fast-Acting Insulin Aspart Ready for Them?Journal of diabetes science and technology · 2018Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUltra-fast-acting insulins, such as fast-acting insulin aspart (faster aspart), have pharmacokinetic properties that may be advantageous for patients using continuous subcutaneous insulin infusion (CSII), provided that they are compatible with and safe to use in CSII.
methodsRandomized, double-blind, parallel-group, actively controlled trial evaluating compatibility, efficacy, and safety of faster aspart in adults with type 1 diabetes using their own MiniMed Paradigm pump with Quick-Set or Silhouette infusion sets. Following run-in, subjects were randomized (2:1) to faster aspart (n = 25) or insulin aspart (n = 12) for 6 weeks. Primary endpoint was the number of microscopically confirmed episodes of infusion-set occlusions.
resultsNo microscopically confirmed episodes of infusion-set occlusions were observed in either arm. Seven possible infusion-set occlusions were reported by five subjects (all faster aspart); none were prompted by a plug observed by the subject (prompted by unexplained hyperglycemia [n = 6] or leakage [n = 1]) and none were confirmed. Macroscopic and microscopic evaluation showed no color change or particle/crystal formation in the infusion sets. Premature infusion-set changes were reported in 44% and 16.7% of subjects in the faster aspart and insulin aspart groups, respectively. A nonsignificant trend toward better efficacy was observed with faster aspart (estimated treatment difference [ETD] [95% CI] in HbA1c change: -0.14% [-0.40, 0.11]). No new safety issues were found in either treatment group.
conclusionsOver 6 weeks of treatment, no microscopically confirmed infusion-set occlusions were observed for faster aspart or insulin aspart, indicating similar compatibility with CSII use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.